Literature DB >> 12493023

Association of maspin expression with the high histological grade and lymphocyte-rich stroma in early-stage breast cancer.

D H Kim1, D S Yoon, W C Dooley, E S Nam, J W Ryu, K C Jung, H R Park, J H Sohn, H S Shin, Y E Park.   

Abstract

AIMS: Maspin is a recently described member of the serpin family or protease inhibitors that is known to be a tumour suppressor gene product. Loss of maspin expression has been found in most breast cancer cases and is correlated with cell motility and tumour invasiveness. However, its precise role in human breast cancer remains to be discovered. We aimed to evaluate the role of maspin in early-stage breast cancer. METHODS AND
RESULTS: We analysed the expression of maspin in 192 stage I and II primary breast cancers by immunohistochemistry. Of these cases, 34.4% showed maspin expression. Maspin expression was more frequently found in invasive ductal carcinoma (36.4%) than in invasive lobular carcinoma (7.1%). High maspin expression was demonstrated in breast cancers showing high histological grade or lymphocyte-rich stroma (P < 0.05). Maspin expression was not associated with overall and disease-free survival rate of breast cancer.
CONCLUSIONS: The results indicate that different biological mechanisms may be responsible for maspin expression in histologically distinct types of breast cancer. Our survey suggests that maspin expression in breast cancer might have a compensatory role rather than prognostic one.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12493023     DOI: 10.1046/j.1365-2559.2003.01567.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

1.  Simultaneous evaluation of maspin and CXCR4 in patients with breast cancer.

Authors:  Efthimia Tsoli; Petros K Tsantoulis; Alexandros Papalambros; Branko Perunovic; David England; David A Rawlands; Gary M Reynolds; Dimitrios Vlachodimitropoulos; Susan L Morgan; Chara A Spiliopoulou; Thanos Athanasiou; Vassilis G Gorgoulis
Journal:  J Clin Pathol       Date:  2006-06-02       Impact factor: 3.411

2.  Maspin Gene Expression in Invasive Ductal Carcinoma of Breast.

Authors:  Shahriar Dabiri; Mohammadmehdi Moeini Aghtaei; Jahanbano Shahryari; Manzume Shamis Meymandi; Sahar Amirpour-Rostami; Reza Foutohi Ardekani
Journal:  Iran J Pathol       Date:  2016

3.  Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer.

Authors:  Meng-Chun Wang; Yan-Min Yang; Xiao-Han Li; Fang Dong; Yan Li
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

4.  Expression of metalloproteases and their inhibitors in different histological types of breast cancer.

Authors:  J M Del Casar; S González-Reyes; L O González; J M González; S Junquera; M Bongera; M F García; A Andicoechea; C Serra; F J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-15       Impact factor: 4.553

5.  Maspin is not required for embryonic development or tumour suppression.

Authors:  Sonia S Y Teoh; Jessica Vieusseux; Monica Prakash; Susan Berkowicz; Jennii Luu; Catherina H Bird; Ruby H P Law; Carlos Rosado; John T Price; James C Whisstock; Phillip I Bird
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

6.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07

7.  Effect of Silibinin on Maspin and ERα Gene Expression in MCF-7 Human Breast Cancer Cell Line.

Authors:  Maryam Karimi; Hossein Babaahmadi-Rezaei; Ghorban Mohammadzadeh; Mohammad-Ali Ghaffari
Journal:  Iran J Pathol       Date:  2017-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.